CA3176912A1 - Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers - Google Patents

Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers

Info

Publication number
CA3176912A1
CA3176912A1 CA3176912A CA3176912A CA3176912A1 CA 3176912 A1 CA3176912 A1 CA 3176912A1 CA 3176912 A CA3176912 A CA 3176912A CA 3176912 A CA3176912 A CA 3176912A CA 3176912 A1 CA3176912 A1 CA 3176912A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
benzo
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176912A
Other languages
English (en)
French (fr)
Inventor
Kevin M. Cottrell
John P. Maxwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tango Therapeutics Inc
Original Assignee
Tango Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tango Therapeutics Inc filed Critical Tango Therapeutics Inc
Publication of CA3176912A1 publication Critical patent/CA3176912A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3176912A 2020-07-31 2021-07-30 Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers Pending CA3176912A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059959P 2020-07-31 2020-07-31
US63/059,959 2020-07-31
PCT/US2021/044004 WO2022026892A1 (en) 2020-07-31 2021-07-30 Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers

Publications (1)

Publication Number Publication Date
CA3176912A1 true CA3176912A1 (en) 2022-02-03

Family

ID=78000758

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176912A Pending CA3176912A1 (en) 2020-07-31 2021-07-30 Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers

Country Status (11)

Country Link
US (5) US11492350B2 (https=)
EP (1) EP4188920A1 (https=)
JP (1) JP2023536589A (https=)
KR (1) KR20230094196A (https=)
CN (1) CN116568677A (https=)
AR (1) AR123127A1 (https=)
AU (1) AU2021319201A1 (https=)
CA (1) CA3176912A1 (https=)
IL (1) IL300147A (https=)
MX (1) MX2023001379A (https=)
WO (1) WO2022026892A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
KR20240148320A (ko) * 2021-12-17 2024-10-11 탱고 테라퓨틱스, 인크. N-(6-아미노-5-메틸피리딘-3-일)-2-(벤조[d]티아졸-5-일)-5-메틸피페리딘-1-일)-2-옥소아세트아마이드의결정질 형태, 약제학적 조성물 및 이의 사용 방법
EP4469438A1 (en) * 2022-01-26 2024-12-04 Tango Therapeutics, Inc. Compounds and methods of use
EP4469447A1 (en) * 2022-01-26 2024-12-04 Tango Therapeutics, Inc. Compounds and methods of use
JP2025504916A (ja) * 2022-01-26 2025-02-19 タンゴ セラピューティクス， インコーポレイテッド 化合物及び使用方法
WO2023146991A1 (en) * 2022-01-26 2023-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2024022433A1 (zh) * 2022-07-28 2024-02-01 北京望实智慧科技有限公司 Prmt5抑制剂
AU2023327684A1 (en) 2022-08-15 2025-03-20 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
CN119744263A (zh) * 2022-08-19 2025-04-01 北京望实智慧科技有限公司 Prmt5抑制剂
CN119731162A (zh) * 2022-08-19 2025-03-28 北京望实智慧科技有限公司 Prmt5抑制剂
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
AU2023366908A1 (en) * 2022-10-25 2025-05-08 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
WO2024104244A1 (zh) * 2022-11-15 2024-05-23 四川科伦博泰生物医药股份有限公司 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2024131918A1 (zh) * 2022-12-22 2024-06-27 成都苑东生物制药股份有限公司 一种取代草酰胺类衍生物、其制备方法及用途
CN120476118A (zh) * 2023-01-17 2025-08-12 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
CN118103373A (zh) 2023-01-18 2024-05-28 上海德琪医药科技有限公司 Prmt5抑制化合物和其用途
CN120457129A (zh) * 2023-01-31 2025-08-08 四川科伦博泰生物医药股份有限公司 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
WO2025016323A1 (zh) 2023-07-14 2025-01-23 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
TW202521525A (zh) 2023-08-09 2025-06-01 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基化合物、其製備方法及其在醫藥上的應用
WO2025039979A1 (zh) 2023-08-18 2025-02-27 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
WO2025059579A1 (en) 2023-09-15 2025-03-20 Ideaya Biosciences, Inc. Methods of treating mat2a related diseases
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
WO2025072544A1 (en) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN120309628A (zh) * 2024-01-13 2025-07-15 艾立康药业股份有限公司 一种prmt5抑制剂及其组合物和药物用途
WO2025166186A1 (en) * 2024-01-31 2025-08-07 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
WO2025166308A1 (en) 2024-01-31 2025-08-07 Tango Therapeutics, Inc. Crystalline forms, pharmaceutical compositions and methods of use thereof
WO2025217297A1 (en) 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer
WO2025218671A1 (en) * 2024-04-16 2025-10-23 Shanghai Apeiron Therapeutics Company Limited Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use
CN121021512A (zh) * 2024-05-28 2025-11-28 艾立康药业股份有限公司 一类prmt5抑制剂及其组合物和用途
WO2025260063A2 (en) 2024-06-13 2025-12-18 Tango Therapeutics, Inc. Methods of preparing a prmt5 inhibitor
WO2026067820A1 (zh) * 2024-09-30 2026-04-02 江苏恒瑞医药股份有限公司 螺杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69622148T2 (de) 1995-09-28 2002-10-31 Suntory Limited, Osaka Chinazozin derivate und deren verwendung
WO2004096774A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170210751A1 (en) 2014-06-25 2017-07-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
US20170280720A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
JP6832430B2 (ja) * 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
EP3939986A1 (en) 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US20190083482A1 (en) 2017-09-18 2019-03-21 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2019084470A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
JP2021505583A (ja) 2017-12-05 2021-02-18 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｍｒｔ５阻害剤としての複素環式化合物
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
US20190175526A1 (en) 2017-12-13 2019-06-13 Macau University Of Science And Technology Methods for treating cancer
US10278955B1 (en) 2017-12-13 2019-05-07 Macau University Of Science And Technology Methods of treating cancer
SMT202200396T1 (it) 2017-12-13 2022-11-18 Lupin Ltd Composti eterociclici biciclici sostituiti come inibitori di prmt5
CA3091041A1 (en) 2018-02-22 2019-08-29 Ichan School Of Medicine At Mount Sinai Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
KR102522856B1 (ko) 2018-03-09 2023-04-19 파마블럭 사이언시스 (난징), 인코포레이티드 단백질 아르기닌 메틸전이효소 5(prmt 5)의 억제제, 이의 약학적 제품 및 이의 방법
WO2019180628A1 (en) 2018-03-22 2019-09-26 Aurigene Discovery Technologies Limited Imidazolidin-2-one compounds as prmt5 modulators
BR112020019111A2 (pt) 2018-03-22 2021-01-12 Aurigene Discovery Technologies Limited Derivados de imidazolidin-2-ona substituída como inibidores de prmt5
WO2019219805A1 (en) 2018-05-16 2019-11-21 Ctxone Pty Ltd Combination therapy
US20210267973A1 (en) 2018-05-31 2021-09-02 Glaxosmithkline Intellectual Property Development Limited Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
CA3118175A1 (en) 2018-11-08 2020-05-14 Glaxosmithkline Intellectual Property Development Limited Combination of prmt5 inhibitors and bcl-2 inhibitors
LT3902803T (lt) * 2018-12-27 2023-04-25 Les Laboratoires Servier Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
EP3924360A1 (en) 2019-02-13 2021-12-22 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
CN113330009B (zh) 2019-03-12 2024-02-09 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
IL318073A (en) 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
WO2020198601A1 (en) 2019-03-27 2020-10-01 University Of Virginia Patent Foundation Combinatorial drug treatment of cancer
WO2020205660A1 (en) 2019-03-29 2020-10-08 University Of Florida Research Foundation, Incorporated Prmt5 inhibitor compounds
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
WO2020206289A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2020206308A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
JP2022526604A (ja) 2019-04-05 2022-05-25 プレリュード・セラピューティクス・インコーポレイテッド タンパク質アルギニンメチルトランスフェラーゼ５の選択的阻害剤
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
WO2021004547A1 (en) 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230062119A1 (en) 2019-12-17 2023-03-02 Merck Sharp & Dohme Llc Use of biomarkers in identifying patients that will be responsive to treatment with a prmt5 inhibitor
CN114929234A (zh) 2020-01-07 2022-08-19 辉瑞公司 用于治疗银屑病及其他自体免疫性病况的方法中的prmt5抑制剂
WO2021163344A1 (en) 2020-02-12 2021-08-19 Amgen Inc. Novel prmt5 inhibitors
WO2022026892A1 (en) * 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
WO2022115377A1 (en) 2020-11-24 2022-06-02 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
UY39565A (es) 2020-12-16 2022-06-30 Amgen Inc Inhibidores de prmt5 novedosos
EP4347569A4 (en) 2021-06-02 2025-03-26 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
WO2023098439A1 (zh) 2021-11-30 2023-06-08 上海和誉生物医药科技有限公司 一种吡唑衍生物，其制备方法和在药学上的应用
CN116462677A (zh) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116462676A (zh) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
US20220127256A1 (en) 2022-04-28
US20260078117A1 (en) 2026-03-19
US20240228478A1 (en) 2024-07-11
US12304907B2 (en) 2025-05-20
WO2022026892A1 (en) 2022-02-03
JP2023536589A (ja) 2023-08-28
US20240279219A1 (en) 2024-08-22
US12264154B2 (en) 2025-04-01
EP4188920A1 (en) 2023-06-07
KR20230094196A (ko) 2023-06-27
US11999727B2 (en) 2024-06-04
CN116568677A (zh) 2023-08-08
MX2023001379A (es) 2023-06-15
AU2021319201A1 (en) 2023-02-16
US20230113778A1 (en) 2023-04-13
TW202220970A (zh) 2022-06-01
US11492350B2 (en) 2022-11-08
IL300147A (en) 2023-03-01
AR123127A1 (es) 2022-11-02

Similar Documents

Publication Publication Date Title
CA3176912A1 (en) Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
US12403137B2 (en) Compounds and methods of use
CA2903813C (en) Carm1 inhibitors and uses thereof
US20240182481A1 (en) Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
US10525060B2 (en) HCK as a therapeutic target in MYD88 mutated diseases
CA2999523A1 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
EP4469438A1 (en) Compounds and methods of use
WO2023146991A1 (en) Compounds and methods of use
WO2016073903A1 (en) Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20250171432A1 (en) Compounds and methods of use
JP7690470B2 (ja) がん幹細胞を標的化するがん治療
EP4469455A1 (en) Compounds and methods of use
US20230192679A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
WO2024173766A1 (en) Cyclin dependent kinase degraders and methods of use thereof
WO2026039676A1 (en) Cyclin dependent kinase degraders and methods of use thereof
WO2026090589A1 (en) Heterocyclic hbs1l degraders
WO2025250667A1 (en) N-(1-(tert-butyl)-1 h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phenyl)acet amide derivatives as ripk2 inhibitors for the treatment of inflammatory diseases
WO2017151625A1 (en) 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250725

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250811

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250815

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250829

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250902

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250909